Cerebrovascular Disease and Associations with ATN Biomarkers and Cognition in Young Onset Dementia

CURRENT STATUS: UNDER REVIEW

Alzheimer's Research & Therapy  BMC

Chathuri Yatawara
National neuroscience institute institute

Kok Pin Ng
National neuroscience institute institute

Anne Cristine Guevarra
National neuroscience institute institute

Benjamin Wong
National neuroscience institute institute

TingTing Yong
National neuroscience institute institute

Nagaendran Kandiah nagaendran_kandiah@nni.com.sg
National Neuroscience Institute
Corresponding Author
ORCiD: 0000-0001-9244-4298

DOI: 10.21203/rs.2.19011/v1

SUBJECT AREAS Cognitive Neuroscience

KEYWORDS
Cerebrovascular disease, Alzheimer’s disease, Cognitive impairment, Amyloid
Abstract

**Background:** Cerebrovascular disease (CVD) and Alzheimer’s disease (AD) frequently coexist however the mechanism by which they collectively affect cognition remains unclear, particularly in young onset dementia (YOD). We investigated associations between CVD and AD biomarkers, namely amyloid, tau and neurodegeneration (ATN) in YOD, and explored how CVD and ATN interact to affect cognition.

**Methods:** 80 YOD individuals with mild dementia, mean age 57.73 (SD = 6.01) years were recruited from a memory clinic. MRI visual ratings were used to operationalize CVD burden (CVD+) as a score >1 on the Staals CVD scale. ATN biomarkers were measured using cerebrospinal fluid (CSF) and cognition was measured using neuropsychological assessments.

**Results:** CVD+ individuals had lower CSF Aβ1-42 compared to CVD- (t[78] = -1.97, p = .05), while demographics, cognition, cardiovascular risk factors, brain volumes and tau were consistent across the groups. CVD+ was associated with lower CSF Aβ1-42 (B = -.20, 95%CI: -.32 to -.08) and greater neurodegeneration, indexed as lower grey matter (B = -.15, 95%CI: -.28 to .02) and hippocampal volume (B = -.24, 95%CI: -.40 to -.04). CVD+ was not associated with p-tau or t-tau. Cognitive impairment was associated with CSF Aβ1-42 (B = -.35, 95%CI: -.55 to -.18) but not CVD. Rather, CVD was indirectly associated with cognition via reduced CSF Aβ1-42, specifically with global cognition (B = -.03, 95%CI: -.09 to -.01) and memory (B = .08, 95%CI: -.09 to -.01). CVD was further indirectly associated with cognition via increased neurodegeneration in total grey matter (Global cognition: B = -.06, 95%CI: -.09 to -.03; Memory: B = .05, 95%CI: .01 to .18) and the hippocampus
Global cognition: $B = -0.05$, 95%CI: -0.11 to -0.01; Memory: $B = 0.06$, 95%CI: 0.01 to 0.17). CVD was not found to moderate the strength or direction of the relationship between ATN and cognition.

**Conclusion:** In YOD, CVD burden is linked to upstream AD mechanisms, such as CSF Aβ$_{1-42}$, as well as downstream neurodegeneration. CVD indirectly contributes to cognitive impairment via these AD mechanisms. Clinical implications support the aggressive management of CVD to delay AD in young adults.

**INTRODUCTION**

Young-onset dementia (YOD) represents individuals with dementia onset before the age of 65 years. YOD is associated with greater economic burden $^1$, more rapid cognitive deterioration and shorter survival compared to late-onset dementia (LOD) $^2$. In addition, patients with YOD are likely to be in paid employment with significant financial commitments and with young children and elders to support. To improve clinical outcomes for this vulnerable group, it is critical to understand disease mechanisms in the young population.

The most common etiology of YOD is Alzheimer’s disease (AD), followed by cerebrovascular disease (CVD) $^3$. Both AD and CVD frequently co-exist and are strong predictors of cognitive impairment and dementia $^4$, $^5$. Imaging biomarkers of CVD include white matter hyperintensities (WMH), lacunes, microbleeds and periventricular spaces $^6$, $^7$. Each of these biomarkers increase the risk of cognitive impairment $^8$–$^{11}$, with executive dysfunctions being the most vulnerable $^{12}$. Biomarkers of AD pathophysiology involve cerebrospinal fluid (CSF) Aβ$_{1-42}$ plaque deposition, tau accumulation and neurodegeneration $^{13}$, $^{14}$, which are collectively
referred to as ATN. Each ATN biomarker has been associated with cognitive decline, with 60%-80% predictive sensitivity compared to healthy controls.

The association between CVD and AD pathology remains controversial. Studies have shown that CVD risk factors, such as pulse pressure, hypertension and diabetes, are associated with abnormal CSF Aβ₁₋₄₂ levels while other studies show that CVD is associated with CSF Tau, independent to Aβ₁₋₄₂. The interaction between Aβ₁₋₄₂ and CVD in the process of cognitive impairment also remains unclear. Some suggest cognitive impairment includes the synergistic effect of both Aβ₁₋₄₂ and CVD, while others suggest both pathologies have independent effects on cognition. Most of these studies have focused on sporadic LOD. As such, little is known about the associations of CVD with AD pathology in patients with YOD. Given young age is a strong moderator of vascular injury and AD pathology, it is imperative to determine the associations between CVD and AD pathophysiology, and their effect on cognition in patients with YOD.

Here, in a cross-sectional study of YOD patients with mild AD, we tested the associations of CVD and ATN biomarkers. We further investigated how CVD and ATN biomarkers interact to affect cognition using moderation and mediation models. We hypothesized that the prevalence of CVD would be associated with a greater burden of ATN biomarkers. We further hypothesized that CVD would moderate the effect of ATN biomarkers on cognition, that is strengthen the associations between ATN and cognition. We also hypothesized a mediation effect where CVD would indirectly be related to cognitive impairment via increasing burden ATN biomarkers. The direction
of CVD affecting ATN biomarkers is in line with pathological studies showing that CVD promotes amyloid aggregation, restrict the clearance of amyloid and causes vascular-related amyloid.

METHODS

Design and setting

Participants

Study participants were selected from the Singapore Young-Onset Dementia Cohort (SYNC), which is a cohort of patients with mild AD experiencing onset of symptoms below the age of 65 years; recruited from a tertiary neurology center (National Neuroscience Institute, Singapore) between 2015–2018. From SYNC, we selected patients with CSF, MRI and neuropsychological assessments (consort diagram in supplementary materials). The diagnosis of mild AD was made based on the NIA-AA Criteria and supported by a Clinical Dementia Rating Scale (CDR) of .05 to 1. Exclusion criteria for the SYNC study included significant neurological or psychiatric comorbidities, a history of alcohol or drug abuse and presence of other neurodegenerative conditions.

Ethics approvals and patient consents

The SYNC study was approved by the Singhealth Centralized Review Board. Informed written consent was obtained from all participants according to Declaration of Helsinki and local clinical research regulations.

Measures

Demographic characteristics, including the participants’ age, gender, race and years of education, were collected using a structured interview with the patient or next of
Cardiovascular risk factors, including blood pressure, diabetes, hyperlipidemia and history of stroke were noted from medical records. Total cerebrovascular burden was indexed using the Framingham office-based cardiovascular disease risk prediction model, which took into account age, gender, BMI, systolic blood pressure, smoking, and diabetes. Cognitive functioning was indexed using global and domain assessments. Global cognition was assessed using the Montreal Cognitive Assessment (MoCA); memory was assessed using the Wechsler Memory Scale version 4 (WMS-IV) Story Recall delayed and immediate tests and (Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) delayed and immediate recall tasks; executive functions was assessed using Frontal Assessment Battery and Color Trails 1 and 2; and visuospatial skills was assessed using the WAIS-IV Block Design test and the Rey Complex Figure test.

CSF

CSF Aβ, phosphorylated tau (ptau) and total tau was collected using a lumbar puncture. ELISA immunoassays were used to process the CSF specimens, in accordance to prescribed protocol and requirements (INNOTEST tTau Ag, INNOTEST PHOSPHO-TAU(181) and INNOTEST β-AMYLOID(1–42); Innogenetics Inc., Alpharetta, GA). CSF cut off based on laboratory parameters: CSF Aβ 1-42 <480pg/mL, phospho tau >61 pg/mL, total tau >425pg/mL (Fujirebio, Ghent, Belgium).

MRI protocol

Patients underwent a 3T MRI scan (Achieva 3.0; Philips Medical Systems, Best, Netherlands) within six months of clinical and neuropsychological evaluation. Scan
specifications include, (a) T1-weighted MPRAGE (axial acquisition, 176 slices, matrix size=256 × 256, voxel size=1.0 × 1.0 × 1.0mm³, echo time (TE)=3.2ms, repetition time (TR)=7ms, inversion time (TI)=850ms, flip angle=8°, field of view (FOV)=256 × 256mm²), and (b) T2-weighted FLAIR imaging (170 slices, matrix size=256 × 256, voxel size=1.0 × 1.0 × 1.0mm³, TE=340ms, TR=8000ms, TI=2400ms, FOV=240 × 240mm²). Scans were visually-rated for WMH using the 0–3 Fazekas Scale on axial FLAIR sequences for deep and periventricular WMH in the left and right hemispheres; lacunes and microbleeds using STandards for Reporting Vascular changes on nEuroimaging (STRIVE); and global cortical atrophy using the Pasquier scale. CVD burden was calculated using the Staals score which combines WMH, lacunes, microbleeds and periventricular spaces into a total CVD-related brain damage score, ranging from 0 - 4. Visual-ratings were performed by independent trained raters and any difference in rating scores were addressed and resolved by consensus.

**Statistical analysis**

*Data preparation* involved imputing variables with less than 30% missing data, based on recommendations by the American Psychological Association Task Force on Statistical Inference. Multiple imputation using the five chained equations procedure was used to perform logistic regression with original weights to estimate grey matter volumes (19% missing) using the predictors age, gender, education, MoCa, CSF Aβ_{1-42}, Fazekas, lacunes, microbleeds and global cortical atrophy.

Patients were grouped as CVD burden (CVD +) based on a Staals score ≥ 1 or the no CVD (CVD -) based on a Staals score of 0. Skewed variables included Staals score, ptau and total tau, and were log transformed. For variables containing 0
Main statistical analysis

1. Group differences between patients with CVD+ and CVD- were determined for demographics, cardiovascular disease risk factors, cognition, CSF biomarkers, grey and white matter volume and CVD markers visually rated from MRI scans. T-test was used for continuous variables, with Welsh adjustment for unequal variances, and \( \chi^2 \) test used for categorical variables.

2. Association between CVD and components of ATN were assessed using a path analysis linear regression model. All ATN components were included in one regression model in order to control for each other. Neurodegeneration was indexed as total tau, total grey matter volume (as a measure of general neurodegeneration) and hippocampal volume (as a measure of AD-specific neurodegeneration). To control for demographics and cardiovascular risk factors, the Framingham cardiovascular risk score was included as a covariate. A post-hoc exploratory analysis investigated the association between CVD and CSF A\( \beta \) on hippocampal atrophy.

3. The direct association of CVD and ATN with cognition was assessed using path analysis regression models, where CVD and ATN components were the predictors and cognition was the outcome. Cognitive outcomes included global cognition, memory, executive functions and visuospatial skills, which were each assessed in independent models. All ATN components were included in each model in order to control for each other and an additional covariate included Framingham risk score. Composite scores for each cognitive domain were created by z-scoring each test and averaging the scores. Population
norms were not used to create z-score because the young age range did not fit in with the locally published norms.

4. **Moderation analysis to determine whether CVD affects the strength or direction of the relationship between ATN and cognition.** To test this a-priori hypothesis, first CVD and ATN components were centered. Next CVD was multiplied with each component of ATN to create the interaction variable. This interaction variable was the predictor in the regression analysis and cognition was the outcome, with Framingham cardiovascular risk score as the covariate. An independent analysis was run for each CVD and ATN interaction variable, and for each cognitive outcome (global cognition and cognitive domains). A post-hoc exploratory analysis investigated the interaction between CVD and \( A\beta_{1-42} \) with hippocampal volume as the outcome.

5. **Mediation analysis to determine whether CVD indirectly affects cognition via the ATN pathway.** This a-priori hypothesis was tested using regression mediation models where the predictor was CVD burden, the outcome was cognitive impairment (indexed using global cognition or cognitive domains) and the mediators were CSF A\( \beta_{1-42} \), CSF tau, CSF total tau and hippocampal volume given it was the only neurodegeneration marker significantly associated with CVD. Each mediator and cognitive outcome was assessed in an independent model with Framingham cardiovascular risk score as the covariate.

As a non-parametric estimation of effects, SEs and biases for all moderation and mediation analyses, bias-corrected (BC) bootstrapping was applied with 1000 resamples \(^{40}\). Bootstrapping measures the variability of the linear approximation of each path in the model and estimates the bias of this linear approximation to the
population. BC bootstrapping has been empirically validated as a tool for multiple comparison correction, deriving robust parameter estimates based on maximized power and limited type 1 error rates. The significance of the BC bootstrap estimate was indicated by confidence intervals that did not contain 0. All moderation and mediation analyses were conducted using path analysis on SPSS AMOS version 20. Path analysis model fit was assessed using published recommended criteria: (a) $\chi^2$ p-value: > 0.05, (b) Bentler comparative fit index (CFI: > 0.95) and (c) root mean error of approximation (RMSEA: < 0.04). Effect sizes for the direct effects were indexed using the standardized coefficient of the slope (B), which is identical to the benchmark set for Pearson’s r; a coefficient of .10, .30 and .50 indicated small, moderate and large effects respectively. Effect size for indirect effects were indexed by squaring Cohen’s estimations because indirect effects represent a product of two effects; a coefficient of .01, .09 and .25 indicated small, moderate and large effects respectively.

Data availability
Deidentified participant data will be made available upon reasonable request from the corresponding author.

RESULTS
1. Group differences
Compared to CVD- patients, CVD+ patients had higher WMH ($t[77] = 4.86, p = .00$) and perivascular spaces ($t[76] = 3.36, p = .00$) (table 1). CVD+ patients were trending on having more lacunes ($t[45] = 1.89, p = .05$), lower CSF Aβ$_{1-42}$ ($t[78] = -1.97, p = .05$) and lower hippocampal volume ($t[78] = -1.91, p = .05$). No
differences were observed with demographics, APOE-4, MoCa, cardiovascular risk factors, Framingham cardiovascular risk score, ptau, total tau, total white and grey matter or number of microbleeds.

2. **Associations between CVD and ATN**

The path analysis regression model with CVD as the predictor and ATN as individual outcomes had excellent model fit according to recommended criteria \(^44\).

*CVD and CSF A\(\beta_{1-42}\)* were negatively associated, while controlling for cardiovascular risk factors, ptau and total tau (\(B = -.20\), SE = .07, bootstrapped \(p = .01\), BC 95%CI: -.32 to -.08).

*CVD and Tau* were not associated.

*CVD and neurodegeneration* indexed as hippocampal volume was negatively associated while controlling for cardiovascular risk factors, CSF A\(\beta_{1-42}\) and ptau (\(B = -.24\), SE = .10, bootstrapped \(p = .04\), BC 95%CI: -.40 to -.04). CVD was not associated with total tau or total grey matter volume.

3. **Direct associations between CVD, ATN and cognition**

The path analysis regression models with CVD and ATN components as the predictors and cognition as the outcome had good model fit according to recommended criteria \(^44\).

*Global cognition* was related to total grey matter volume (\(B = .41\), SE = .01, bootstrapped \(p = .00\), BC 95%CI: .02 to .06) and hippocampal volume (\(B = .34\), SE = 71, bootstrapped \(p = .00\), BC 95%CI: 1.25 to 3.91), while controlling for cardiovascular risk factors, CSF A\(\beta_{1-42}\), ptau, and CVD. Global cognition was not related to CVD, CSF A\(\beta_{1-42}\), CSF p-tau and CSF t-tau.

*Memory* was associated with CSF A\(\beta_{1-42}\) (\(B = -.35\), SE = .00, bootstrapped \(p = .00\),
BC95%CI: -0.55 to -0.18), while controlling for cardiovascular risk factors, ptau, total tau and CVD. Memory was associated with total grey matter volume (B = -0.25, SE = 0.00, bootstrapped p = 0.02, BC95%CI: -0.01 to -0.00), and hippocampal atrophy (B = -0.27, SE = 0.05, bootstrapped p = 0.04, BC95%CI: -0.21 to -0.01) while controlling for cardiovascular risk factors, CSF Aβ1-42, ptau and CVD. A trend was observed between memory and CVD (B = 0.18, SE = 0.05, bootstrapped p = 0.08, BC95%CI: -0.00 to 0.33), while controlling for cardiovascular risk factors, CSF Aβ1-42, ptau and total tau.

Executive functions were not associated with CVD, CSF Aβ1-42, ptau, total tau, total grey matter volume or hippocampal atrophy.

Visuospatial functions were associated with the three markers of neurodegeneration: total tau (B = -0.56, SE = 0.27, bootstrapped p = 0.04, BC95%CI: -1.07 to -0.16), total grey matter volume (B = 0.48, SE = 0.00, bootstrapped p = 0.00, BC95%CI: 0.00 to 0.01) and hippocampal volume (B = 0.42, SE = 0.10, bootstrapped p = 0.01, BC95%CI: 0.15 to 0.51), while controlling for cardiovascular risk factors, CSF Aβ1-42, ptau, and CVD.

4. The moderating role of ATN on the effect of CVD and cognition

The path analysis regression models with CVD interacting with ATN as the predictors and cognition or hippocampal volume as the outcome had excellent model fit according to recommended criteria. CVD did not interact with CSF Aβ1-42, ptau or total tau to affect global cognition or cognitive domains. A post-hoc analysis indicated that CVD did not interact with CSF Aβ1-42 to affect hippocampal volumes.

5. The mediating role of ATN on the effect of CVD on cognition
The path analysis regression models with CVD as the predictor, ATN as the mediators and cognition or hippocampal volume as the outcome had excellent model fit according to recommended criteria \(^{44}\).

*Global cognition:* An indirect association was observed between CVD and global cognition, as mediated by CSF A\(_{\beta} \, 1-42\), controlling for cardiovascular risk factors, ptau and total tau (table 2). CVD was also indirectly related to global cognition as mediated by total grey matter volume and hippocampal atrophy, while controlling for cardiovascular risk factors, CSF A\(_{\beta} \, 1-42\) and ptau.

*Memory:* An indirect association was observed between CVD and memory, as mediated by CSF A\(_{\beta} \, 1-42\), while controlling for cardiovascular risk factors, ptau and hippocampal atrophy (table 2). CVD was also mediated by total grey matter volume and hippocampal atrophy in its association with memory.

*Executive functions/Visuospatial functions:* CVD was not indirectly related to executive functions or visuospatial functions, as mediated by ATN.

**DISCUSSION**

**Main findings**

In a young cohort of patients with mild AD, we showed that the prevalence of CVD burden was highly concomitant with the prevalence of low CSF A\(_{\beta} \, 1-42\), even after controlling for age, gender, education, cognition, cardiovascular risk factors and grey and white matter volume. CVD was associated with lower CSF A\(_{\beta} \, 1-42\) and greater neurodegeneration in AD specific regions, namely the hippocampus. Meanwhile no associations were observed between CVD and p-tau or total tau. Cognitive impairment was directly associated with low CSF A\(_{\beta} \, 1-42\), but not with
CVD. Rather, CVD was indirectly associated with global and memory impairment via reduced CSF Aβ\textsubscript{1−42} levels and increased neurodegeneration in total grey matter and specifically in the hippocampus. CVD was not found to moderate the strength or direction of the relationship between ATN and cognition. Our findings suggest that CVD is linked to the ATN pathway in patients with YOD and indirectly drives cognitive impairment via this pathway.

Associations between CVD, Amyloid and Neurodegeneration

Amyloid is believed to be first in a line of upstream effects that cause AD-related dementia\textsuperscript{13}. Our findings suggest that in YOD patients, CVD is associated with earlier mechanisms of the AD process, namely Aβ\textsubscript{1−42} deposition. Possible mechanisms of this association may involve the vascular system promoting Aβ\textsubscript{1−42} aggregation\textsuperscript{23}, restricting clearance of Aβ\textsubscript{1−42}\textsuperscript{24} and causing vascular-related Aβ\textsubscript{1−42}\textsuperscript{25}. Our findings in YOD are in comparison to past research in patients with LOD, where CVD was found to exhibit a more delayed effect on the ATN sequelae by affecting tau aggregation\textsuperscript{19}. Thus it appears that in young age, CVD precipitates the AD process by influencing Aβ\textsubscript{1−42}, while in old age CVD may simply lower the threshold for AD symptomology.

CVD and CSF Aβ\textsubscript{1−42} were each associated with AD-pattern neurodegeneration, namely hippocampal atrophy. CVD did not interact with Aβ\textsubscript{1−42} to affect hippocampal atrophy, suggesting each mechanism had an independent effect on neurodegeneration. This is consistent with previous in-vivo studies demonstrating that while hippocampal volume loss is similar between AD and small vessel disease, the cause of neural loss differs; neural loss in AD was caused by amyloid deposition
and neural loss in small vessel disease was caused by microvasculature pyramidal cell loss. Therefore, CVD and CSF Aβ_1–42 may each have additive effects on AD-pattern neurodegeneration, resulting from different pathogenic mechanisms.

Associations between CVD and Amyloid with Cognition

Low CSF Aβ_1–42 was associated with memory impairment. A moderate effect size suggests that YOD patients with low Aβ_1–42 may exhibit observable memory deficits. On the contrary, mild CVD was not directly associated with cognitive impairment nor did it interact with Aβ_1–42 to affect cognition. CVD also did not interact with Aβ_1–42 to affect neurodegeneration. Thus despite being associated, CVD and Aβ_1–42 work independently to effect both cognitive impairment and neurodegeneration. Comparatively, studies with LOD cohorts have demonstrated CVD predicts cognitive decline both alone and in some cases synergistically with Aβ_1–42. Thus it is likely that young age may protect against the effects of mild CVD on cognition, however may not protect against the effects of AD pathology on cognition.

One mechanism by which CVD was related to cognitive impairment was indirectly via increasing neurodegeneration and lowering CSF Aβ_1–42. This was observed for both global cognition and memory. The former indirect effect suggests that neural loss may be critical for CVD to manifest clinically in YOD patients. The later indirect effect suggests that while CVD is not related to clinical outcomes in YOD, it is related to other disease mechanisms such as amyloid accumulation. We further note that the size of the mediation effect was small when the outcome was global cognitive impairment, while effect size was moderate when the outcome was
memory; suggesting that the effect of CVD lowering CSF Aβ_1−42 may be most detrimental for memory functions.

Limitations and future research

We note that the current study recruited patients from the SYNC cohort that underwent lumbar puncture. As a result, patients included in the study had lower cognition and greater depressive symptoms compared to the overall SYNC cohort, resulting in selection bias towards poorer functioning patients (supplementary materials). We note that the mean CSF Aβ_1−42 level in our cohort was in the normal range, while the Tau levels were in the abnormal range, suggesting AD in our cohort could have been predominantly Tau driven. We note that these findings are relevant to a clinic based cohort and an Asian population. We further note we did not have a comparison group. Future research would benefit from comparing YOD with LOD from a single cohort to ensure consistency in methodology.

Conclusion

In YOD patients with mild AD, CVD and low CSF Aβ_1−42 may co-exist. Cognitive impairment in this young population was directly associated with low CSF Aβ_1−42, but not with CVD. Rather, CVD precipitated upstream and downstream phases of the ATN pathway, which consequently led to cognitive impairment. Thus, CVD related mechanisms may accelerate AD pathology in younger patients with negative consequences on cognition at later ages. Clinical implications support the aggressive management of CVD as a potential approach to delay AD in young adults.

 Declarations
Ethics approval and consent to participate

The study was approved by the Singhealth Centralized Review Board. Informed written consent was obtained from all participants according to Declaration of Helsinki and local clinical research regulations.

Consent for publication

Not applicable

Availability of data and materials

The dataset analyzed during the current study are not publically available but is available upon reasonable request from the corresponding author.

Competing interests

The authors declare that they have no competing interests

Funding

This study was funded by National Medical Research Council (NMRC/CIRG/1416/2015).

Author's contributions

CY contributed to the study conception and design, analysis of data and drafting the manuscript. KN contributed to revising the manuscript for intellectual content. AG, BW and TY contributed to acquisition and management of data. NK contributed to the conception and design of the study, and revising the manuscript for intellectual content.

Acknowledgements

We thank the National Neuroscience Institute and the patients for supporting this study.

References
1. Kandiah N, Wang V, Lin X, et al. Cost related to dementia in the young and the impact of etiological subtype on cost. Journal of Alzheimer's Disease 2016;49:277-285.

2. Raskind MA, Carta A, Bravi D. Is early-onset Alzheimer disease a distinct subgroup within the Alzheimer disease population? Alzheimer disease and associated disorders 1995;9:S2-6.

3. Vieira RT, Caixeta L, Machado S, et al. Epidemiology of early-onset dementia: a review of the literature. Clinical practice and epidemiology in mental health: CP & EMH 2013;9:88.

4. Ye BS, Seo SW, Kim GH, et al. Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimer's & Dementia 2015;11:494-503. e493.

5. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 2015;138:761-771.

6. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014;83:1228-1234.

7. Wardlaw J, Smith E, Biessels G, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822-838.

8. Akoudad S, Wolters FJ, Viswanathan A, et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA neurology 2016;73:934-943.
9. Prasad K, Wiryasaputra L, Ng A, Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer’s disease in a clinic cohort. Dementia and geriatric cognitive disorders 2011;31:431-434.

10. Jokinen H, Gouw A, Madureira S, et al. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011;76:1872-1878.

11. MacLullich A, Wardlaw J, Ferguson K, Starr J, Seckl J, Deary I. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. Journal of Neurology, Neurosurgery & Psychiatry 2004;75:1519-1523.

12. Kalaria R. Associations between lesions and domain-specific cognitive decline in poststroke dementia. Neurology 2018:10.1212/WNL. 0000000000005734.

13. Jack CR, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539-547.

14. Jack Jr CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia 2018;14:535-562.

15. MedCalc for Windows, version 15.0. (MedCalc Software, Ostend, Belgium).

16. Hampel H, Teipel S, Fuchsberger T, et al. Value of CSF β-amyloid 1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular psychiatry 2004;9:705.

17. Nation DA, Edland SD, Bondi MW, et al. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology 2013;81:2024-2027.

18. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk
factors for β-amyloid deposition in healthy aging: vascular and genetic effects.
JAMA neurology 2013;70:600-606.

19. Vemuri P, Lesnick TG, Przybelski SA, et al. Age, vascular health, and Alzheimer
disease biomarkers in an elderly sample. Annals of neurology 2017;82:706-718.

20. Park J-H, Seo SW, Kim C, et al. Effects of cerebrovascular disease and amyloid
beta burden on cognition in subjects with subcortical vascular cognitive
impairment. Neurobiology of aging 2014;35:254-260.

21. Lee MJ, Seo SW, Na DL, et al. Synergistic effects of ischemia and β-amyloid
burden on cognitive decline in patients with subcortical vascular mild cognitive
impairment. JAMA psychiatry 2014;71:412-422.

22. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovascular disease, beta-
amyloid, and cognition in aging. Neurobiology of aging 2012;33:1006. e1025-
1006. e1036.

23. Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor 1α (HIF-1α)-mediated
hypoxia increases BACE1 expression and β-amyloid generation. Journal of
Biological Chemistry 2007;282:10873-10880.

24. Hachinski V, Munoz DG. Cerebrovascular pathology in Alzheimer's disease:
cause, effect or epiphenomenon? Annals of the New York Academy of Sciences
1997;826:1-6.

25. Han BH, Zhou M-l, Abousaleh F, et al. Cerebrovascular dysfunction in amyloid
precursor protein transgenic mice: contribution of soluble and insoluble
amyloid-β peptide, partial restoration via γ-secretase inhibition. Journal of
Neuroscience 2008;28:13542-13550.

26. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due
to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia 2011;7:263-269.

27. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993.

28. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. Circulation 2008;117:743-753.

29. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 2005;53:695-699.

30. Wechsler D. Wechsler memory scale-(WMS-IV). New York: The Psychological Corporation 2009.

31. Chu L, Chiu K, Hui S, Yu G, Tsui W, Lee P. The reliability and validity of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong. Annals of the Academy of Medicine, Singapore 2000;29:474-485.

32. Dubuois B, Slachevsky A, Litvan I, Pillon B. The FAB A frontal assessment battery at bedside. Neurology 2000;55:1621-1626.

33. D'Elia L, Satz P. Color trails test: Psychological Assessment Resources, 1996.

34. Wechsler D. Wechsler adult intelligence scale-fourth: San Antonio: Pearson, 2008.

35. Shin M-S, Park S-Y, Park S-R, Seol S-H, Kwon JS. Clinical and empirical applications of the Rey-Osterrieth complex figure test. Nature protocols 2006;1:892.

36. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental
MRI white matter signal hyperintensities. Neurology 1993;43:1683-1683.

37. Wardlaw J, Smith E, Biessels G, et al. STandards for Reporting Vascular changes on nEuromaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822-838.

38. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. European neurology 1996;36:268-272.

39. Wilkinson L. Statistical methods in psychology journals: guidelines and explanations. American psychologist 1999;54:594.

40. Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychological methods 2002;7:422.

41. Hesterberg TC. What teachers should know about the bootstrap: Resampling in the undergraduate statistics curriculum. The American Statistician 2015;69:371-386.

42. Westfall PH. On using the bootstrap for multiple comparisons. Journal of biopharmaceutical statistics 2011;21:1187-1205.

43. Arbuckle J. IBM SPSS Amos 20. Version 20.0. Chicago: SPSS, 2011.

44. Schreiber JB, Nora A, Stage FK, Barlow EA, King J. Reporting structural equation modeling and confirmatory factor analysis results: A review. The Journal of educational research 2006;99:323-338.

45. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.). New York, NY: Academic Press, 1988.

46. Hayes AF. Introduction to mediation, moderation, and conditional process analysis: A regression-based approach: Guilford Press, 2013.
Kril J, Patel S, Harding A, Halliday G. Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery & Psychiatry 2002;72:747-751.

### Tables

**Table 1. Participant characteristics**

|                          | Total cohort (N = 80) | CVD + (N = 47) | CVD - (N= 33) |
|--------------------------|-----------------------|----------------|---------------|
| **Demographics**         |                       |                |               |
| Age                      | 57.73 (6.01)          | 57.60 (6.39)   | 57.92 (5.50)  |
| Gender (Males)           | 35 (44%)              | 21 (45%)       | 14 (42%)      |
| Education                | 11.91 (4.48)          | 11.85 (4.34)   | 12 (4.74)     |
| APOE-e4                  | 18 (35%)              | 13 (28%)       | 5 (15%)       |
| **Cardiovascular risk factors** |                   |                |               |
| Diabetes                 | 14 (17%)              | 7 (15%)        | 7 (21%)       |
| Hypertension             | 30 (37%)              | 21 (45%)       | 9 (27%)       |
| History of stroke        | 6 (7%)                | 3 (6%)         | 3 (9%)        |
| Hyperlipidemia           | 36 (45%)              | 23 (49%)       | 13 (39%)      |
| Framingham risk score    | 11.79 (3.64)          | 12.12 (3.68)   | 11.75 (3.64)  |
| **Cognition**            |                       |                |               |
| Moca                     | 19.97 (7.03)          | 18.47 (7.04)   | 21.39 (6.75)  |
| FAB                      | 13.71 (4.26)          | 13.18 (4.33)   | 14.54 (4.09)  |
| Color trails I           | 129.52 (176.40)       | 156.90 (217.45)| 88.44 (70.2)  |
| Color trails II          | 164.89 (133.17)       | 176.21 (132.53)| 148.93(135.66)|
| ADAS immediate recall    | 5.00 (2.40)           | 5.56 (2.45)    | 4.09 (2.05)   |
| ADAS delayed recall      | 5.43 (3.68)           | 6.31 (3.67)    | 4.00 (3.28)   |
| Story recall immediate   | 8.38 (6.02)           | 7.68 (6.16)    | 9.52 (5.72)   |
| Block design             | 29.56 (15.02)         | 26.71 (15.10)  | 34.08 (14.03) |
| RCFT                     | 26.73 (11.35)         | 25.35 (12.09)  | 28.94 (9.90)  |
| **CSF biomarkers**       |                       |                |               |
| Aβ 1-42 (pg/ml)          | 811.09 (391.53)       | 740.05 (357.69)| 912.27 (420.18)|
| pTau (pg/ml)             | 68.34 (42.94)         | 68.91 (44.88)  | 67.54 (40.71)  |
| Total Tau (pg/ml)        | 493.70 (378.50)       | 511.90 (393.76)| 467.77 (360.01)|

*p < 0.05, *p < 0.01, **p < 0.001.
### Abbreviations:

| CVD markers | (Mean, SD, median, IQR) | Staals score | .59 (SD = .49), 1, IQR = 4 | 1.23 (SD = .69), 1, IQR = 3 | 0 (SD = 0), 0, IQR = 0^a  

**Fazekas score** | 4.65 (SD = 4.09), 4, IQR = 12 | 6.74 (SD = 3.65), 6, IQR = 12 | 1.88 (SD= 2.79), 0, IQR = 0^a  

Lacunes | .28 (SD= 1.31), 0, IQR = 11 | .47, (SD = 1.67), 0, IQR = 11 | 0, 0, 0 IQR = 0^a  

Microbleeds | .33 (SD=2.13), 0, IQR = 15 | .57, (SD = 2.77), 0, IQR = 15 | 0, 0, 0, IQR =0^a  

Perivascular spaces | 2.32 (SD=2.15), 2, IQR = 6 | 3.15 (SD = 2.09), 3, IQR =6 | 1.15 (SD = .166), 0, IQR = 6^a  

### MRI volumes

| Total grey matter | 586.72 (SD = 68.52) | 575.03 (SD = 67.54) | 603.33 (SD = 67.42)^a  

Total white matter | 483.93 (SD = 61.62) | 479.47 (SD = 63.01) | 490.29 (SD = 59.98)^a  

Hippocampal grey matter | 6.12 (SD = 1.03) | 5.94 (SD = 1.08) | 6.38 SD = ( SD=.91)^a  

---

**Table 2.** Regression weights for the indirect associations between CVD and cognition as mediated by ATN.
| Variable                              | B    | SE   | BC95% CI  |
|--------------------------------------|------|------|-----------|
| CVD à Aβ 1-42 à Moca                  | -.03 | .02  | -.09 to -.01 |
| CVD à pTau à Moca                    | .01  | .02  | -.02 to .04  |
| CVD à Total Tau à Moca               | -.01 | .03  | -.09 to .03  |
| CVD à Total grey matter à Moca       | -.06 | .04  | -.17 to -.03  |
| CVD à Hippocampus à Moca             | -.05 | .03  | -.11 to -.01  |

Memory

| Variable                              | B    | SE   | BC95% CI  |
|--------------------------------------|------|------|-----------|
| CVD à Aβ 1-42 à Memory               | .08  | .05  | .01 to .21  |
| CVD à pTau à Memory                  | .03  | .04  | -.02 to .09  |
| CVD à Total Tau à Memory             | .03  | .05  | -.01 to .13  |
| CVD à Total grey matter à Memory     | .05  | .04  | .01 to .18  |
| CVD à Hippocampus à Memory           | .06  | .04  | .01 to .17  |

**Abbreviations:** B: standardized beta; SE: standard error; CI: confidence interval

*bootstrapped p < .05, **bootstrapped p < .01

[1] Total available genetics data N= 31 CVD+ (18 missing) and N= 20 CVD- (13 missing)

**Figures**
Figure 1

The direct and indirect effect of CVD burden on cognitive impairment, via the ATβ

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to
download.

SUPPLEMENTARY MATERIAL Final.docx